| Literature DB >> 27853246 |
Zhen Yang1, Chonghuai Yan2, Gang Liu3, Yixin Niu1, Weiwei Zhang1, Shuai Lu4, Xiaoyong Li1, Hongmei Zhang1, Guang Ning5, Jiangao Fan6, Li Qin1,4, Qing Su1.
Abstract
Selenium exposure can induce liver insulin resistance and increased liver triglyceride concentrations in animals, which may link to an increased risk of nonalcoholic fatty liver disease (NAFLD). However, epidemiological studies investigating the association between elevated plasma selenium levels and NAFLD were not available. We aimed to investigate the association of selenium levels with the prevalence of NAFLD in Chinese adults. This was a cross-sectional study of 8550 Chinese adults aged 40 yr or older in Shanghai, China. A questionnaire, anthropometric measurements, and laboratory tests were conducted. NAFLD was diagnosed by hepatic ultrasound after the exclusion of alcohol abuse and other liver diseases. Plasma selenium concentration was assessed by inductively coupled plasma mass spectroscopy. The median concentration of plasma selenium was 213.0 μg/L. Elevated plasma selenium levels were associated with higher triglycerides, LDL-cholesterol, fasting plasma glucose, post-loading plasma glucose, A1c, HOMA-IR, as well as ALT, AST and γ-GT (all P < 0.05). The odds ratios were substantially higher for NAFLD (OR = 1.54, 95% CI 1.13-2.18) in the highest selenium quartile compared with those in the lowest quartile, after adjustment for potential cofounder. The results of this study provided epidemiological evidence that increased plasma selenium level is associated with elevated prevalence of NAFLD.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27853246 PMCID: PMC5112507 DOI: 10.1038/srep37288
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of participants according to plasma selenium quartiles.
| Q1: <181.6 μg/L | Q2: 181.6–213.0 μg/L | Q3: 213.0–247.4 μg/L | Q4: >247.4 μg/L | P for trend | |
|---|---|---|---|---|---|
| Selenium (mg/l) | 0.16 (0.15–0.17) | 0.20 (0.19–0.21) | 0.23 (0.22–0.24) | 0.27 (0.26–0.30) | <0.001 |
| Age (years) | 56.1 ± 8.0 | 55.8 ± 8.0 | 56.1 ± 7.8 | 56.3 ± 7.9 | 0.26 |
| Female | (62.8) | (69.5) | (66.2) | (64.2) | 0.35 |
| Current smokers | (15.6) | (12.8) | (14.1) | (19.9) | <0.001 |
| Physical activity | 0.97 | ||||
| Low | (72.5) | (71.4) | (70.2) | (73.1) | |
| Moderate | (21.4) | (19.8) | (20.3) | (19.4) | |
| High | (6.1) | (8.8) | (9.5) | (7.5) | |
| Body mass index (kg/m2) | 24.7 ± 3.5 | 24.5 ± 3.4 | 24.3 ± 3.2 | 24.8 ± 3.8 | 0.27 |
| Waist circumference (cm) | 83.2 ± 9.5 | 83.3 ± 9.5 | 83.7 ± 9.6 | 84.9 ± 9.8 | 0.005 |
| Systolic blood pressure (mmHg) | 129.5 ± 20.3 | 131.8 ± 17.8 | 130.2 ± 17.9 | 134.5 ± 21.2 | 0.001 |
| Diastolic blood pressure (mmHg) | 81.8 ± 10.8 | 81.0 ± 10.6 | 80.1 ± 10.8 | 81.2 ± 11.1 | 0.28 |
| Triglycerides (mmol/l) | 1.32 (0.91–1.84) | 1.34 (1.00–2.10) | 1.47 (1.01–2.22) | 1.57 (1.07–2.39) | <0.001 |
| Total cholesterol (mmol/l) | 4.89 ± 0.92 | 4.72 ± 0.99 | 4.88 ± 0.98 | 4.94 ± 0.97 | 0.01 |
| High-density lipoprotein cholesterol (mmol/l) | 1.29 ± 0.32 | 1.27 ± 0.32 | 1.30 ± 0.31 | 1.28 ± 0.31 | 0.76 |
| Low-density lipoprotein cholesterol (mmol/l) | 2.63 ± 0.75 | 2.69 ± 0.78 | 2.73 ± 0.76 | 2.73 ± 0.76 | 0.034 |
| Fasting plasma glucose (mmol/l) | 6.23 ± 1.35 | 6.28 ± 1.95 | 6.41 ± 1.90 | 6.71 ± 2.25 | <0.001 |
| Post-loading plasma glucose (mmol/l) | 8.52 ± 3.59 | 8.72 ± 3.67 | 8.93 ± 3.96 | 9.57 ± 4.32 | <0.001 |
| Hemoglobin A1c (%) | 5.6 (5.3–6.0) | 5.9 (5.5–6.4) | 6.1 (5.7–6.5) | 6.2 (5.8–6.7) | <0.001 |
| HOMA-IR | 1.66 (1.19–2.50) | 1.68 (1.21–2.58) | 1.74 (1.27–2.65) | 1.82 (1.29–2.90) | <0.001 |
| C-reactive protein (mg/l) | 1.37 (0.55–3.41) | 1.49 (0.62–3.67) | 1.55 (0.64–3.65) | 1.43 (0.53–3.39) | 0.57 |
| eGFR (ml/min per 1.73 m2) | 121.1 ± 25.0 | 122.2 ± 24.2 | 120.6 ± 20.5 | 121.8 ± 22.9 | 0.34 |
| ALT (U/L) | 14 (10–20) | 15 (11–20) | 16 (12–21) | 17 (12–23) | <0.001 |
| AST (U/L) | 20 (16–24) | 21 (17–25) | 21 (18–26) | 22 (19–27) | <0.001 |
| γ-GT (U/L) | 19 (13–31) | 20 (14–32) | 21 (14–34) | 22 (15–40) | <0.001 |
Abbreviations: Q, quartile; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyltranspeptidase.
Data are means ± s.d. or medians (interquartile ranges) or numbers (proportions).
Clinical and laboratory characteristics of NAFLD and control subjects.
| Without NAFLD group (n = 5118) | NAFLD group (n = 3732) | P value | |
|---|---|---|---|
| Age (years) | 55.4 ± 7.9 | 57.0 ± 7.3 | <0.001 |
| Sex (male/female) | 1749/3069 | 990/2742 | <0.001 |
| Systolic blood pressure (mmHg) | 128.4 ± 19.3 | 133.6 ± 18.5 | <0.001 |
| Diastolic blood pressure (mmHg) | 79.1 ± 10.3 | 82.0 ± 10.0 | <0.001 |
| Waist circumference (cm) | 81.2 ± 10.3 | 89.2 ± 8.6 | <0.001 |
| Body mass index (kg/m2) | 23.3 ± 3.0 | 26.4 ± 6.2 | <0.001 |
| Triglycerides (mmol/l) | 1.1 (0.9–1.6) | 1.8 (1.4–2.6) | <0.001 |
| Total cholesterol (mmol/l) | 4.6 ± 0.9 | 4.8 ± 1.1 | <0.001 |
| High-density lipoprotein cholesterol (mmol/l) | 1.29 ± 0.33 | 1.14 ± 0.27 | <0.001 |
| Low-density lipoprotein cholesterol (mmol/l) | 2.54 ± 0.76 | 2.69 ± 0.80 | <0.001 |
| Fasting plasma glucose (mmol/l) | 6.0 ± 1.5 | 6.6 ± 2.0 | <0.001 |
| Post-loading plasma glucose (mmol/l) | 7.8 ± 3.3 | 9.8 ± 4.3 | <0.001 |
| HbA1c (%) | 5.8 ± 0.8 | 6.2 ± 1.0 | <0.001 |
| HOMA-IR | 1.5 (1.1–1.9) | 2.5 (1.8–3.4) | <0.001 |
| C-reactive protein (mg/l) | 1.45 (0.56–3.47) | 1.51 (0.63–3.79) | <0.001 |
| eGFR (ml/min per 1.73 m2) | 124.9 (110.6–140.3) | 121.3 (106.9–135.8) | <0.001 |
| ALT (U/l) | 14.3 ± 10.1 | 21.4 ± 15.6 | <0.001 |
| AST (U/l) | 19.3 ± 8.8 | 22.5 ± 12.3 | <0.001 |
| γ-GT (U/l) | 24.0 ± 28.1 | 37.2 ± 48.3 | <0.001 |
| Selenium (μg/L) | 192.5 (182.3–203.9) | 270.2 (256.4–288.5) | <0.001 |
Abbreviations: HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyltranspeptidase.
Data are means ± s.d. or medians (interquartile ranges) or numbers (proportions).
Odds ratio (95% confidence interval) of nonalcoholic fatty liver disease according to quartiles of plasma selenium concentrations.
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend | |
|---|---|---|---|---|---|
| <181.6 μg/L | 181.6–213 μg/L | 213.1–247.4 μg/L | >247.4 μg/L | ||
| No. cases/participants | 613/2212 | 809/2213 | 1145/2212 | 1165/2213 | |
| Model 1 | 1 | 1.29 (0.99–1.77) | 1.79 (1.26–2.37) | 1.60 (1.17–2.18) | <0.001 |
| Model 2 | 1 | 1.29 (0.98–1.78) | 1.75 (1.22–2.34) | 1.58 (1.15–2.18) | <0.001 |
| Model 3 | 1 | 1.24 (0.96–1.77) | 1.70 (1.16–2.32) | 1.52 (1.11–2.14) | <0.001 |
| Model 4 | 1 | 1.27 (0.95–1.77) | 1.72 (1.19–2.33) | 1.54 (1.13–2.18) | <0.001 |
aModel 1: adjusted for age, gender.
bModel 2: additionally adjusted for BMI, current smoking status, drinking status, physical activity.
cModel 3: additionally adjusted for waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, post-loading plasma glucose, HOMA-IR, lipid profiles and estimated glomerular filtration rate.
dModel 4: additionally adjusted for liver enzyme profiles and C-reactive protein.
Figure 1Odds ratio of nonalcoholic fatty liver diseases by log-transformed plasma selenium concentrations.
Lines represent odds ratios (95% CI) based on restricted cubic splines for log-transformed plasma selenium concentrations with knots at the 5th, 50th and 95th percentiles. Odds ratios were estimated using a logistic regression model after adjustment for age, gender, BMI, current smoking status, physical activity, waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, post-loading plasma glucose, HOMA-IR, lipid profiles, estimated glomerular filtration rate and C-reactive protein; P for linear <0.01. Bars represent the numbers of participants, 6 equally sized bins were selected from the 1st to the 99th percentiles of log-transformed selenium distribution.
Figure 2Stratified analyses of the associations [odds ratio (95% confidence interval)] between plasma selenium concentrations and nonalcoholic fatty liver diseases.
aAdjusted for age, gender, BMI, current smoking status, physical activity, waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, post-loading plasma glucose, HOMA-IR, lipid profiles, estimated glomerular filtration rate and C-reactive protein, stratifying factors excepted.